A New Webinar Exclusively for MedPro and Princeton Insureds

 

Keep the Infection Out of the Injection

 

Healthcare providers are often unaware of actions and behaviors that lead to healthcare-associated infections (HAIs) and disease transmission in their practices. This webinar will address injection practices in the United States, highlight recent outbreaks, and assess the impact of unsafe injections on patient safety and professional licensure. Objectives 1.  Discuss increased focus on HAIs and injection safety. 2.  Discuss safe injection practices and common injection safety breaches. 3.  Describe outbreaks linked to poor infection practices.

 

Wednesday, April 16, 2014, 12:00 – 1:30 p.m. Eastern Time This webinar is available at no cost for Medical Protective and Princeton insureds and offers 1.5 CME with full documented participation. To receive CME credit, each participant must register and sign in on a separate computer for the webinar.   REGISTER HERE  https://www1.gotomeeting.com/register/797200528

A Proactive Approach to Addressing Patient Safety Risks Associated With the 2012 Fungal Meningitis Outbreak

Medical Protective 10/18/12

 

The recent outbreak of fungal meningitis in the United States and subsequent recall of
a contaminated steroid medication have created concerns about patient safety and
liability among a number of Medical Protective’s insureds.
According to reports, the outbreak, which has been linked to an epidural steroid
injection produced and distributed by a specialty compounding pharmacy in
Massachusetts, has claimed 12 lives as of October 9, 2012. The pharmacy in question,
the New England Compounding Center (NECC), voluntarily recalled three lots of the
contaminated steroid (methylprednisolone acetate) on September 25, 2012. Less than
two weeks later, following a recommendation from the U.S. Food and Drug
Administration (FDA), NECC issued a voluntary recall of all of its products.
As of the date above, the Centers for Disease Control and Prevention (CDC) reports
that medical facilities in 23 states received the contaminated steroids, with nine states
reporting cases of fungal meningitis as of early October. States affected include
Indiana, Florida, Maryland, Michigan, Minnesota, New Jersey, North Carolina, Ohio,
Tennessee, and Virginia. Experts reportedly believe that more cases will emerge over
the coming days and weeks. For a list of states and facilities that received the recalled
lots of methylprednisolone acetate, visit

http://www.cdc.gov/hai/outbreaks/meningitisfacilities-map.html.
According to the CDC, the potentially contaminated injections were given beginning
May 21, 2012. Symptoms typically develop one to four weeks following injection and
may include fever, new or worsening headache, neck stiffness, sensitivity to light, new
weakness or numbness, increasing pain, and redness or swelling of the injection site.
In response to ongoing concerns, Medical Protective offers its insureds the following
risk strategies—in addition to relevant guidance from the CDC and the FDA—to address
issues related to the meningitis outbreak:
1. Determine if your medication inventory contains any products made or
distributed by NECC. These products have been recalled, and they should be
removed from circulation pursuant to CDC and/or FDA instruction.
2. Determine if your medication inventory includes any of the following lot
numbers that, according to current reports, have been linked to the fungal
meningitis outbreak:
a. Methylprednisolone Acetate (PF) 80 mg/ml Injection, Lot #05212012@68,
BUD 11/17/2012
b. Methylprednisolone Acetate (PF) 80 mg/ml Injection, Lot #06292012@26,
BUD 12/26/2012
c. Methylprednisolone Acetate (PF) 80 mg/ml Injection, Lot #08102012@51,
BUD 2/6/2013
3. Any identified inventory as described by 1 or 2 above (the “NECC Inventory”)
should be removed from circulation pursuant to CDC and/or FDA instruction.
Additionally, you should continue to review the CDC website to determine if any
other products require removal from your inventory.
4. Perform a current medication inventory audit. Be sure to include a review of
the record of medications previously received and administered, as they may no
longer be in your inventory. Then do the following:
a. Document that you performed the inventory audit, including dates and
times.
b. If your inventory includes items from the NECC Inventory, document the
steps you took to ensure the medication was pulled from your inventory,
including dates and times and how you sequestered the affected
medication. Take special care to document any lot numbers identified
by the CDC which appeared in your audit.
c. If your inventory does not contain items from the NECC Inventory,
document that you verified that your office did not receive or administer
any items from the NECC Inventory.
􀀹 Design and implement a communication plan to notify patients
who have received a “safe” injection, but who still may have
concerns.
5. If you confirm receipt of NECC Inventory items and administration of such items
to patients, audit all of your patient records to determine who might have
received the injections.
a. If any of your patients have received injections of NECC Inventory
items, document this fact in each of their charts. Be careful to focus on
your concern for patient safety, rather than on possible liability for the
drug manufacturer. Consider monitoring any such patients.
b. Design and implement a plan to notify patients who received an
injection from a CDC identified lot. Ensure that your office/facility staff
communicates a consistent message.
􀀹 Advise patients of the common symptoms of fungal meningitis.
􀀹 Advise patients where to seek help should they experience any
of the symptoms. Consider advising referral to their local
emergency department (ED). Also, consider including a
reference to patient resources, including the ED, on your out-ofoffice
voicemail message.
c. Contact your town’s local ED(s) to advise them of whether any of your
patients received an injection from a CDC-identified lot, and to put them
on notice of a potential influx of patients.
d. Contact your local health department to alert them about affected CDC
identified lots of medication within your inventory. Your health
department will be able to communicate this information to the broader
physician community in a timely manner, while maintaining
confidentiality.
6. Continually monitor relevant resources, including CDC and FDA resources, for
updates regarding the most current information and instruction.
a. Medical Protective advises its insureds to follow specific guidance from
the CDC and FDA on how to handle issues associated with the fungal
meningitis outbreak.
b. Information can be found at
http://www.cdc.gov/hai/outbreaks/clinicians/
index.html. If you have any additional questions or concerns, please
contact your regional risk management consultant or call 800–
4MEDPRO.
The information and guidance contained in this release is intended to supplement, but
not replace, other available information and/or instruction from the United States
Government.